Emily B Ehlerding

List of Publications by Year
in descending order

39 papers	2,157 citations	304743 22 h-index	302126 39 g-index
39 all docs	39 docs citations	39 times ranked	3662 citing authors

#	Article	IF	Citations
1	NanoLuc: A Small Luciferase Is Brightening Up the Field of Bioluminescence. Bioconjugate Chemistry, 2016, 27, 1175-1187.	3.6	383
2	Theranostic Nanoparticles. Journal of Nuclear Medicine, 2014, 55, 1919-1922.	5.0	235
3	*In Vivo* Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine. ACS Nano, 2015, 9, 3926-3934.	14.6	155
4	Preclinical Pharmacokinetics and Biodistribution Studies of ^{89}Zr-Labeled Pembrolizumab. Journal of Nuclear Medicine, 2017, 58, 162-168.	5.0	152
5	A Melanin‐Based Natural Antioxidant Defense Nanosystem for Theranostic Application in Acute Kidney Injury. Advanced Functional Materials, 2019, 29, 1904833.	14.9	111
6	89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 110-120.	6.4	100
7	Noninvasive PET Imaging of T cells. Trends in Cancer, 2018, 4, 359-373.	7.4	88
8	ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer. Molecular Pharmaceutics, 2017, 14, 1782-1789.	4.6	84
9	Molecular Imaging of Immunotherapy Targets in Cancer. Journal of Nuclear Medicine, 2016, 57, 1487-1492.	5.0	77
10	Chelator‐Free Radiolabeling of Nanographene: Breaking the Stereotype of Chelation. Angewandte Chemie - International Edition, 2017, 56, 2889-2892.	13.8	65
11	Multimodality Imaging Agents with PET as the Fundamental Pillar. Angewandte Chemie - International Edition, 2019, 58, 2570-2579.	13.8	62
12	CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody. Theranostics, 2016, 6, 1918-1933.	10.0	57
13	Aptamer-Conjugated Framework Nucleic Acids for the Repair of Cerebral Ischemia-Reperfusion Injury. Nano Letters, 2019, 19, 7334-7341.	9.1	51
14	Molecular imaging of Î²-cells: diabetes and beyond. Advanced Drug Delivery Reviews, 2019, 139, 16-31.	13.7	42
15	CD146‐Targeted Multimodal Image‐Guided Photoimmunotherapy of Melanoma. Advanced Science, 2019, 6, 1801237.	11.2	42
16	Site-Specific Immuno-PET Tracer to Image PD-L1. Molecular Pharmaceutics, 2019, 16, 2028-2036.	4.6	41
17	Dual-Targeted Molecular Imaging of Cancer. Journal of Nuclear Medicine, 2018, 59, 390-395.	5.0	37
18	PET Imaging of Receptor Tyrosine Kinases in Cancer. Molecular Cancer Therapeutics, 2018, 17, 1625-1636.	4.1	35

#	Article	IF	Citations
19	Chelator-Free Labeling of Metal Oxide Nanostructures with Zirconium-89 for Positron Emission Tomography Imaging. ACS Nano, 2017, 11, 12193-12201.	14.6	34
20	Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with [89]Zr–Df–Atezolizumab. Bioconjugate Chemistry, 2019, 30, 1434-1441.	3.6	34
21	Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1296-1305.	6.4	31
22	PET and SPECT imaging of melanoma: the state of the art. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 132-150.	6.4	29
23	CD38 as a PET Imaging Target in Lung Cancer. Molecular Pharmaceutics, 2017, 14, 2400-2406.	4.6	25
24	Antibody‐Based Tracers for PET/SPECT Imaging of Chronic Inflammatory Diseases. ChemBioChem, 2019, 20, 422-436.	2.6	23
25	"Albumin Hitchhiking" with an Evans Blue Analog for Cancer Theranostics. Theranostics, 2018, 8, 812-814.	10.0	20
26	Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models. Molecular Pharmaceutics, 2018, 15, 1627-1634.	4.6	19
27	86/90Y-Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics. Molecular Pharmaceutics, 2020, 17, 1697-1705.	4.6	19
28	Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models. American Journal of Cancer Research, 2019, 9, 53-63.	1.4	19
29	Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 123-131.	6.4	17
30	Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection. American Journal of Cancer Research, 2019, 9, 1454-1468.	1.4	11
31	Harnessing the Power of Molecular Imaging for Precision Medicine. Journal of Nuclear Medicine, 2016, 57, 171-172.	5.0	9
32	Cancer theranostics with 64Cu/177Lu-loaded liposomes. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 938-940.	6.4	9
33	Chelator‐Free Radiolabeling of Nanographene: Breaking the Stereotype of Chelation. Angewandte Chemie, 2017, 129, 2935-2938.	2.0	9
34	Smaller Agents for Larger Therapeutic Indices: Nanoscale Brachytherapy with ^{177}Lu-Labeled Gold Nanoparticles. Journal of Nuclear Medicine, 2016, 57, 834-835.	5.0	8
35	Multimodale Kontrastmittel für die kombinierte Positronenemissionstomographie. Angewandte Chemie, 2019, 131, 2592-2602.	2.0	8
36	ImmunoPET imaging of CD38 expression in hepatocellular carcinoma using Cu-labeled daratumumab. American Journal of Translational Research (discontinued), 2019, 11, 6007-6015.	0.0	8

#	Article	IF	Citations
37	Imaging the Biodistribution and Performance of Transplanted Stem Cells with PET. Journal of Nuclear Medicine, 2016, 57, 1331-1332.	5.0	5
38	One-step synthesis of an 18F-labeled boron-derived methionine analog: a substitute for 11C-methionine?. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 582-584.	6.4	2
39	Predicting PD-1/PD-L1 status in bladder cancer with 18F-FDG PET?. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 791-793.	6.4	1